BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.82
+2.61%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -21.2%
- EBIT
- -15.1%
- EPS
- +99.9%
- Free cash flow
- -33.7%
- Operating cash flow
- -28.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +11.0%
- EBIT
- +10.1%
- Net income
- -9.0%
- EPS
- +89.2%
- Free cash flow
- +58.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025